Blood tests may reveal who will get severe COVID-19

NCT ID NCT04668170

Completed Knowledge-focused Sponsor: University Hospital, Toulouse Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This completed study analyzed blood samples from 304 COVID-19 patients in France to find early immune markers that predict whether someone will become severely ill. Researchers looked at T-cells and inflammatory chemicals in the blood to understand why some people worsen while others recover. The goal is to help doctors tailor treatments earlier based on a patient's immune response.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this could help doctors identify early which COVID-19 patients are at risk of severe illness, allowing for quicker, more personalized treatment.
What could go wrong: This is an observational study, not a treatment trial. The findings may not lead to immediate clinical changes and need further validation in larger, diverse groups.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COVID-19 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

COVID-19

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COVID-19

Contacts and locations

Show contact details

Locations

University Hospital Bordeaux

Bordeau, 33000, France
University Hospital Toulouse

Toulouse, 31059, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.